Journal Mobile Options
Table of Contents
Vol. 24, No. 4, 2002
Issue release date: July–August (December 2002)
Dev Neurosci 2002;24:255–261
(DOI:10.1159/000066746)

White Matter Injury, Neural Connectivity and the Pathophysiology of Psychiatric Disorders

Kumar A. · Cook I.A.
Department of Psychiatry and The Neuropsychiatric Institute, University of California, LosAngeles,Calif.,USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Psychiatric disorders are characterized by diverse clinical manifestations that include deficits in cognition, perception, mood and arousal. These complex processes are not mediated by any specific brain region but require the coordinated activity of several areas that are anatomically connected. Impairments in these neural circuits may therefore be expected to result in an attenuation of the functions regulated by them. The white matter provides the structural and physiological substrate of neural circuits in the central nervous system. We propose that injury to the white matter, from diverse biological sources, may compromise neural connectivity by associated axonal injury or impaired conductivity. Either mechanism could result in clusters of signs and symptoms that are currently recognized as psychiatric disorders. The role of white matter impairment in the pathophysiology of psychiatric illness is under-appreciated in the neurosciences. Focused translational research aimed at identifying the links between white matter compromise and specific behaviors are necessary for a more thorough understanding of the etiology of mental illness to emerge.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fuster JM: The prefrontal cortex – an update: Time is of the essence. Neuron 2001;30:319–333.

    External Resources

  2. Mesulam M: Principles of Behavioral Neurology. Philadelphia, Davis, 1985.
  3. Filley CM: The behavioral neurology of cerebral white matter. Neurology 1998;50:1535–1540.
  4. Filley C: The Behavioral Neurology of White Matter. New York, Oxford University Press, 2001.
  5. Silbersweig DA, Stern E, Frith C, Cahill C, Holmes A, Grootoonk S, Seaward J, McKenna P, Chua SE, Schnorr L: A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995;378:176–179.
  6. Goldman-Rakic P: Circuitry of primate prefrontal cortex and regulation of behavior by representational memory; in Plum F (ed): Handbook of Physiology: The Nervous System, sect 1, vol V. Bethesda, American Physiological Society, 1987, pp 373–417.
  7. Geula C: Abnormalities of neural circuitry in Alzheimer’s disease: Hippocampus and cortical cholinergic innervation. Neurology 1998;51:S18–S29.
  8. Akbarian S, Kim JJ, Potkin SG, Hetrick WP, Bunney WE Jr, Jones EG: Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996;53:425–436.
  9. Ommaya AK, Gennarelli TA: Cerebral concussion and traumatic unconsciousness. Correlation of experimental and clinical observations of blunt head injuries. Brain 1974;97:633–654.
  10. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M: ‘Vascular depression’ hypothesis. Arch Gen Psychiatry 1997;54:915–922.
  11. Bjartmar C, Yin X, Trapp BD: Axonal pathology in myelin disorders. J Neurocytol 1999;28:383–395.
  12. Thomas AJ, Ferrier IN, Kalaria RN, Perry RH, Brown A, O’Brien JT: A neuropathological study of vascular factors in late-life depression. J Neurol Neurosurg Psychiatry 2001;70:83–87.
  13. Morris JS, Smith KA, Cowen PJ, Friston KJ, Dolan RJ: Covariation of activity in habenula and dorsal raphe nuclei following tryptophan depletion. Neuroimage 1999;10:163–172.
  14. Geschwind N: Disconnexion syndromes in animals and man. II. Brain 1965;88:585–644.
  15. Wallin A, Blennow K, Uhlemann C, Langstrom G, Gottfries CG: White matter low attenuation on computed tomography in Alzheimer’s disease and vascular dementia – diagnostic and pathogenetic aspects. Acta Neurol Scand 1989;80:518–523.
  16. Buchsbaum MS, Tang CY, Peled S, Gudbjartsson H, Lu D, Hazlett EA, Downhill J, Haznedar M, Fallon JH, Atlas SW: MRI white matter diffusion anisotropy and PET metabolic rate in schizophrenia. Neuroreport 1998;9:425–430.
  17. Lim KO, Adalsteinsson E, Spielman D, Sullivan EV, Rosenbloom MJ, Pfefferbaum A: Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 1998;55:346–352.
  18. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, Breteler MM: Cerebral white matter lesions and cognitive function: The Rotterdam Scan Study. Ann Neurol 2000;47:145–151.
  19. Gunning-Dixon FM, Raz N: The cognitive correlates of white matter abnormalities in normal aging: A quantitative review. Neuropsychology 2000;14:224–232.
  20. Kreutzer JS, Seel RT, Gourley E: The prevalence and symptom rates of depression after traumatic brain injury: A comprehensive examination. Brain Inj 2001;15:563–576.
  21. Nicholl CR, Lincoln NB, Francis VM, Stephan TF: Assessment of emotional problems in people with multiple sclerosis. Clin Rehabil 2001;15:657–668.
  22. O’Sullivan M, Jones DK, Summers PE, Morris RG, Williams SC, Markus HS: Evidence for cortical ‘disconnection’ as a mechanism of age-related cognitive decline. Neurology 2001;57:632–638.
  23. Kumar A, Thomas MA, Lavretsky H, Yue K, Huda A, Curran J, Venkatraman T, Estanol L, Mintz J, Mega M, Toga A: Frontal white matter biochemical abnormalities in late-life major depression detected using proton magnetic resonance spectroscopy, in press.
  24. Kumar A, Mintz J, Bilker W, Gottlieb G: Autonomous neurobiological pathways to late-life major depression disorder: Clinical and pathophysiological implications. Neuropsychopharmacology 2002;26:229–236.
  25. Cook IA, Leuchter AF, Morgan ML, Witte E, David S, Lufkin R, Babaie A, Dunkin JJ, O’Hara R, Simon S, Lightner A, Thomas S, Broumandi D, Badjatia N, Mickes L, Mody R, Arroyo S, Zheng Z, Abrams M, Rosenberg-Thompson S: Cognitive and physiologic correlates of subclinical structural brain disease in elderly normal controls. Arch Neurol, in press.
  26. Harrison JE, O’Callaghan FJ, Hancock E, Osborne JP, Bolton PF: Cognitive deficits in normally intelligent patients with tuberous sclerosis. Am J Med Genet 1999;88:642–646.
  27. Hyde TM, Ziegler JC, Weinberger DR: Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992;49:401–406.
  28. Rosebush PI, Garside S, Levinson AJ, Mazurek MF: The neuropsychiatry of adult-onset adrenoleukodystrophy. J Neuropsychiatry Clin Neurosci 1999;11:315–327.
  29. Brassington JC, Marsh NV: Neuropsychological aspects of multiple sclerosis. Neuropsychol Rev 1998;8:43–77.
  30. Feinstein A, Kartsounis LD, Miller DH, Youl BD, Ron MA: Clinically isolated lesions of the type seen in multiple sclerosis: A cognitive, psychiatric, and MRI follow up study. J Neurol Neurosurg Psychiatry 1992;55:869–876.
  31. Sadovnick AD, Eisen K, Ebers GC, Paty DW: Cause of death in patients attending multiple sclerosis clinics. Neurology 1991;41:1193–1196.
  32. Evangelou N, Esiri MM, Smith S, Palace J, Matthews PM: Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol 2000;47:391–395.
  33. Honer WG, Hurwitz T, Li DK, Palmer M, Paty DW: Temporal lobe involvement in multiple sclerosis patients with psychiatric disorders. Arch Neurol 1987;44:187–190.
  34. Adams JH, Graham DI, Jennett B: The neuropathology of the vegetative state after an acute brain insult. Brain 2000;123 (pt 7):1327–1338.
  35. Adams JH, Graham DI, Murray LS, Scott G: Diffuse axonal injury due to nonmissile head injury in humans: An analysis of 45 cases. Ann Neurol 1982;12:557–563.
  36. Alexander M: The role of neurobehavioral syndromes in the rehabilitation and outcome of closed head injury; in Levin H, Grafman J, Eisenberg H (eds): Neurobehavioral Recovery from Head Injury. New York, Oxford University Press, 1987, pp 191–205.
  37. Filley CM, Cranberg LD, Alexander MP, Hart EJ: Neurobehavioral outcome after closed head injury in childhood and adolescence. Arch Neurol 1987;44:194–198.
  38. van Reekum R, Cohen T, Wong J: Can traumatic brain injury cause psychiatric disorders? J Neuropsychiatry Clin Neurosci 2000;12:316–327.
  39. McAllister TW: Neuropsychiatric sequelae of head injuries. Psychiatr Clin North Am 1992;15:395–413.
  40. Bennett DA, Gilley DW, Lee S, Cochran EJ: White matter changes: Neurobehavioral manifestations of Binswanger’s disease and clinical correlates in Alzheimer’s disease. Dementia 1994;5:148–152.
  41. Stuss D, Cummings J: Subcortical vascular dementia; in Cummings J (ed): Subcortical Dementia. New York, Oxford University Press, 1990, pp 145–163.
  42. Tournier-Lasserve E, Joutel A, Melki J, Weissenbach J, Lathrop GM, Chabriat H, Mas JL, Cabanis EA, Baudrimont M, Maciazek J: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993;3:256–259.
  43. Dichgans M, Filippi M, Bruning R, Iannucci G, Berchtenbreiter C, Minicucci L, Uttner I, Crispin A, Ludwig H, Gasser T, Yousry TA: Quantitative MRI in CADASIL: Correlation with disability and cognitive performance. Neurology 1999;52:1361–1367.
  44. Galasko D, Kwo-On-Yuen PF, Thal L: Intracranial mass lesions associated with late-onset psychosis and depression. Psychiatr Clin North Am 1988;11:151–166.
  45. Steffens DC, Bosworth HB, Provenzale JM, MacFall JR: Subcortical white matter lesions and functional impairment in geriatric depression. Depress Anxiety 2002;15:23–28.
  46. Krishnan KR, Hays JC, Blazer DG: MRI-defined vascular depression. Am J Psychiatry 1997;154:497–501.
  47. Kato T, Hamakawa H, Shioiri T, Murashita J, Takahashi Y, Takahashi S, Inubushi T: Choline-containing compounds detected by proton magnetic resonance spectroscopy in the basal ganglia in bipolar disorder. J Psychiatry Neurosci 1996;21:248–254.
  48. Hamakawa H, Kato T, Murashita J, Kato N: Quantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci 1998;248:53–58.
  49. Murata T, Kimura H, Omori M, Kado H, Kosaka H, Iidaka T, Itoh H, Wada Y: MRI white matter hyperintensities 1H-MR spectroscopy and cognitive function in geriatric depression: A comparison of early- and late-onset cases. Int J Geriatr Psychiatry 2001;16:1129–1135.
  50. Taylor WD, Payne ME, Krishnan KR, Wagner HR, Provenzale JM, Steffens DC, MacFall JR: Evidence of white matter tract disruption in MRI hyperintensities. Biol Psychiatry 2001;50:179–183.
  51. Foong J, Symms MR, Barker GJ, Maier M, Woermann FG, Miller DH, Ron MA: Neuropathological abnormalities in schizophrenia: Evidence from magnetization transfer imaging. Brain 2001;124:882–892.
  52. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085–1098.
  53. Rajkowska G: Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000;48:766–777.
  54. Duman RS: Windows on the human brain and the neurobiology of psychiatric illness. Neuropsychopharmacology 2002;26:141–142.
  55. Catalaa I, Fulton JC, Zhang X, Udupa JK, Kolson D, Grossman M, Wei L, McGowan JC, Polansky M, Grossman RI: MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. AJNR Am J Neuroradiol 1999;20:1613–1618.
  56. Thomas MA, Yue K, Binesh N, Davanzo P, Kumar A, Siegel B, Frye M, Curran J, Lufkin R, Martin P, Guze B: Localized two-dimensional shift correlated MR spectroscopy of human brain. Magn Reson Med 2001;46:58–67.
  57. Gitelman DR, Nobre AC, Parrish TB, LaBar KS, Kim YH, Meyer JR, Mesulam M: A large-scale distributed network for covert spatial attention: Further anatomicl delineation based on stringent behavioural and cognitive controls. Brain 1999;122 (pt 6):1093–1106.
  58. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R, Goldberg TE, Weinberger DR: Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000;10:1078–1092.
  59. Lewis DA: The human brain revisited: Opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology 2002;26:143–154.
  60. Campagnoni AT, Skoff RP: The pathobiology of myelin mutants reveals novel biological functions of the MBP and PLP genes. Brain Pathol 2001;11:74–91.


Pay-per-View Options
Direct payment This item at the regular price: USD 9.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 8.00